Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Human Amnion Membrane Allograft and Early Return of Erectile Function After Radical Prostatectomy
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 03, 2023
BioDFence® G3 For Full Nerve-Sparing Robotic-Assisted Radical Prostatectomy
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 06, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Musculoskeletal
Study Phase : Undisclosed
Recipient : The Hawkins Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Steroid Injection vs. BioDRestore for Patients With Knee OA
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 10, 2016
Lead Product(s) : Undisclosed
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Recipient : The Hawkins Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Collagenase Inhibitor
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MEDIHONEY® Gel Versus Collagenase for Wound Debridement
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
June 26, 2015
Lead Product(s) : Collagenase Inhibitor
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Propolis
Therapeutic Area : Oncology
Study Phase : Undisclosed
Recipient : University of Maryland, Baltimore
Deal Size : Inapplicable
Deal Type : Inapplicable
MediHoney for Radiation Dermatitis
Details : Undisclosed
Product Name : MediHoney
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 09, 2014
Lead Product(s) : Propolis
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Recipient : University of Maryland, Baltimore
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
May 09, 2013
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
April 25, 2013
Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
April 12, 2013
Lead Product(s) : Integra Flowable Matrix Collagen
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Recipient : Georgetown University
Deal Size : Inapplicable
Deal Type : Inapplicable
Use of INTEGRAâ„¢ Flowable Wound Matrix to Manage Diabetic Foot Ulcers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 21, 2010
Lead Product(s) : Integra Flowable Matrix Collagen
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Recipient : Georgetown University
Deal Size : Inapplicable
Deal Type : Inapplicable